Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Hematology & Oncology
Published in: Journal of Hematology & Oncology 1/2022

Open Access 01-12-2022 | Melanoma | Review

Emerging role of RNA sensors in tumor microenvironment and immunotherapy

Authors: Rui Yang, Sihui Yu, Tianhan Xu, Jiawen Zhang, Sufang Wu

Published in: Journal of Hematology & Oncology | Issue 1/2022

Login to get access

Abstract

RNA sensors detect foreign and endogenous RNAs to protect the host by initiating innate and adaptive immune response. In tumor microenvironment (TME), activation of RNA sensors induces tumor-inhibitory cytotoxic T lymphocyte responses and inhibits the activity of immunosuppressive cells though stimulating type I IFN signaling pathway. These characteristics allow RNA sensors to be prospective targets in tumor immunotherapy. Therefore, a comprehensive understanding of the roles of RNA sensors in TME could provide new insight into the antitumor immunotherapy. Moreover, RNA sensors could be prominent triggering targets to synergize with immunotherapies. In this review, we highlight the diverse mechanisms of RNA sensors in cancer immunity and their emerging contributions in cancer immunotherapy, including monotherapy with RNA sensor agonists, as well as combination with chemotherapy, radiotherapy, immune checkpoint blockade or cancer vaccine.
Literature
1.
2.
Qiao Y, Zhu S, Deng S, et al. Human cancer cells sense cytosolic nucleic acids through the RIG-I-MAVS pathway and cGAS-STING pathway. Front Cell Dev Biol. 2021;8:606001.PubMedPubMedCentralCrossRef
3.
4.
Cui J, Chen YJ, Wang HY, et al. Mechanisms and pathways of innate immune activation and regulation in health and cancer. Hum Vaccine Immunother. 2014;10(11):3270–85.CrossRef
5.
6.
Alexopoulou L, Holt AC, Medzhitov R, et al. Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature. 2001;413(6857):732–8.PubMedCrossRef
7.
8.
Zhang ZK, Ohto U, Shibata T, et al. Structural analysis reveals that Toll-like receptor 7 is a dual receptor for guanosine and single-stranded RNA. Immunity. 2016;45(4):737–48.PubMedCrossRef
9.
Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell. 2006;124(4):783–801.PubMedCrossRef
10.
Chan CP, Jin DY. Cytoplasmic RNA sensors and their interplay with RNA-binding partners in innate antiviral response: theme and variations. RNA. 2022;28(4):449–77.PubMedPubMedCentralCrossRef
11.
Andrejeva J, Childs KS, Young DF, et al. The V proteins of paramyxoviruses bind the IFN-inducible RNA helicase, mda-5, and inhibit its activation of the IFN-beta promoter. Proc Natl Acad Sci U S A. 2004;101(49):17264–9.PubMedPubMedCentralCrossRef
12.
Yoneyama M, Kikuchi M, Natsukawa T, et al. The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses. Nat Immunol. 2004;5(7):730–7.PubMedCrossRef
13.
Kato H, Takeuchi O, Mikamo-Satoh E, et al. Length-dependent recognition of double-stranded ribonucleic acids by retinoic acid-inducible gene-I and melanoma differentiation-associated gene 5. J Exp Med. 2008;205(7):1601–10.PubMedPubMedCentralCrossRef
14.
Hornung V, Ellegast J, Kim S, et al. 5’-Triphosphate RNA is the ligand for RIG-I. Science. 2006;314(5801):994–7.PubMedCrossRef
15.
Schlee M, Roth A, Hornung V, et al. Recognition of 5’ triphosphate by RIG-I helicase requires short blunt double-stranded RNA as contained in panhandle of negative-strand virus. Immunity. 2009;31(1):25–34.PubMedPubMedCentralCrossRef
16.
Chow KT, Gale M, Loo YM. RIG-I and other RNA sensors in antiviral immunity. Annu Rev Immunol. 2018;36:667–94.PubMedCrossRef
17.
Yoneyama M, Kikuchi M, Matsumoto K, et al. Shared and unique functions of the DExD/H-box helicases RIG-I, MDA5, and LGP2 in antiviral innate immunity. J Immunol. 2005;175(5):2851–8.PubMedCrossRef
18.
Seth RB, Sun LJ, Ea CK, et al. Identification and characterization of MAVS, a mitochondrial antiviral signaling protein that activates NF-kappaB and IRF3. Cell. 2005;122(5):669–82.PubMedCrossRef
19.
Maurano M, Snyder JM, Connelly C, et al. Protein kinase R and the integrated stress response drive immunopathology caused by mutations in the RNA deaminase ADAR1. Immunity. 2021;54(9):1948-1960.e5.PubMedCrossRef
20.
Zitvogel L, Galluzzi L, Kepp O, et al. Type I interferons in anticancer immunity. Nat Rev Immunol. 2015;15(7):405–14.PubMedCrossRef
21.
Tatematsu M, Seya T, Matsumoto M. Beyond dsRNA: Toll-like receptor 3 signalling in RNA-induced immune responses. Biochem J. 2014;458(2):195–201.PubMedCrossRef
22.
Estornes Y, Toscano F, Virard F, et al. dsRNA induces apoptosis through an atypical death complex associating TLR3 to caspase-8. Cell Death Differ. 2012;19(9):1482–94.PubMedPubMedCentralCrossRef
23.
Lomphithak T, Choksi S, Mutirangura A, et al. Receptor-interacting protein kinase 1 is a key mediator in TLR3 ligand and Smac mimetic-induced cell death and suppresses TLR3 ligand-promoted invasion in cholangiocarcinoma. Cell Commun Signal. 2020;18(1):161.PubMedPubMedCentralCrossRef
24.
Zemek RM, Jong ED, Chin WL, et al. Sensitization to immune checkpoint blockade through activation of a STAT1/NK axis in the tumor microenvironment. Sci Transl Med. 2019;11(501):eaav7816.PubMedCrossRef
25.
Azuma M, Takeda Y, Nakajima H, et al. Biphasic function of TLR3 adjuvant on tumor and spleen dendritic cells promotes tumor T cell infiltration and regression in a vaccine therapy. Oncoimmunology. 2016;5(8):e1188244.PubMedPubMedCentralCrossRef
26.
Shime H, Matsumoto M, Oshiumi H, et al. Toll-like receptor 3 signaling converts tumor-supporting myeloid cells to tumoricidal effectors. Proc Natl Acad Sci U S A. 2012;109(6):2066–71.PubMedPubMedCentralCrossRef
27.
Jongbloed SL, Kassianos AJ, McDonald KJ, et al. Human CD141+ (BDCA-3)+ dendritic cells (DCs) represent a unique myeloid DC subset that cross-presents necrotic cell antigens. J Exp Med. 2010;207(6):1247–60.PubMedPubMedCentralCrossRef
28.
Spranger S, Dai D, Horton B, et al. Tumor-residing Batf3 dendritic cells are required for effector T cell trafficking and adoptive T cell therapy. Cancer Cell. 2017;31(5):711-723.e4.PubMedPubMedCentralCrossRef
29.
Böttcher JP, Bonavita E, Chakravarty P, et al. NK cells stimulate recruitment of cDC1 into the tumor microenvironment promoting cancer immune control. Cell. 2018;172(5):1022-1037.e14.PubMedPubMedCentralCrossRef
30.
Kline DE, MacNabb BW, Chen XF, et al. CD8alpha(+) dendritic cells dictate leukemia-specific CD8(+) T cell fates. J Immunol. 2018;201(12):3759–69.PubMedCrossRef
31.
Hubert M, Gobbini E, Couillault C, et al. IFN-III is selectively produced by cDC1 and predicts good clinical outcome in breast cancer. Sci Immunol. 2020;5(46):eaav3942.
32.
Lee YS, O'Brien LJ, Walpole CM, et al. Human CD141(+) dendritic cells (cDC1) are impaired in patients with advanced melanoma but can be targeted to enhance anti-PD-1 in a humanized mouse model. J Immunother Cancer. 2021;9(3):e001963.
33.
Bianchi F, Alexiadis S, Camisaschi C, et al. TLR3 expression induces apoptosis in human non-small-cell lung cancer. Int J Mol Sci. 2020;21(4):1440.PubMedCentralCrossRef
34.
Vidyarthi A, Khan N, Agnihotri T, et al. TLR-3 stimulation skews M2 macrophages to M1 through IFN-alphabeta signaling and restricts tumor progression. Front Immunol. 2018;9:1650.PubMedPubMedCentralCrossRef
35.
Le Noci V, Tortoreto M, Gulino A, et al. Poly(I:C) and CpG-ODN combined aerosolization to treat lung metastases and counter the immunosuppressive microenvironment. Oncoimmunology. 2015;4(10):e1040214.PubMedPubMedCentralCrossRef
36.
Le Noci V, Sommariva M, Tortoreto M, et al. Reprogramming the lung microenvironment by inhaled immunotherapy fosters immune destruction of tumor. Oncoimmunology. 2016;5(11):e1234571.PubMedPubMedCentralCrossRef
37.
Sommariva M, Le Noci V, Storti C, et al. Activation of NK cell cytotoxicity by aerosolized CpG-ODN/poly(I:C) against lung melanoma metastases is mediated by alveolar macrophages. Cell Immunol. 2017;313:52–8.PubMedCrossRef
38.
Thomas G, Micci L, Yang W, et al. Intra-tumoral activation of endosomal TLR pathways reveals a distinct role for TLR3 agonist dependent type-1 interferons in shaping the tumor immune microenvironment. Front Oncol. 2021;11:711673.PubMedPubMedCentralCrossRef
39.
Chen J, Sun W, Zhang H, et al. Macrophages reprogrammed by lung cancer microparticles promote tumor development via release of IL-1beta. Cell Mol Immunol. 2020;17(12):1233–44.PubMedCrossRef
40.
41.
Barr TA, Brown S, Ryan G, et al. TLR-mediated stimulation of APC: distinct cytokine responses of B cells and dendritic cells. Eur J Immunol. 2007;37(11):3040–53.PubMedPubMedCentralCrossRef
42.
Dajon M, Iribarren K, Petitprez F, et al. Toll like receptor 7 expressed by malignant cells promotes tumor progression and metastasis through the recruitment of myeloid derived suppressor cells. Oncoimmunology. 2019;8(1):e1505174.PubMedCrossRef
43.
Michaelis KA, Norgard MA, Zhu X, et al. The TLR7/8 agonist R848 remodels tumor and host responses to promote survival in pancreatic cancer. Nat Commun. 2019;10(1):4682.PubMedPubMedCentralCrossRef
44.
Grimmig T, Matthes N, Hoeland K, et al. TLR7 and TLR8 expression increases tumor cell proliferation and promotes chemoresistance in human pancreatic cancer. Int J Oncol. 2015;47(3):857–66.PubMedPubMedCentralCrossRef
45.
Chatterjee S, Crozet L, Damotte D, et al. TLR7 promotes tumor progression, chemotherapy resistance, and poor clinical outcomes in non-small cell lung cancer. Cancer Res. 2014;74(18):5008–18.PubMedCrossRef
46.
Yuan Q, Zhou Q, Ren J, et al. WGCNA identification of TLR7 as a novel diagnostic biomarker, progression and prognostic indicator, and immunotherapeutic target for stomach adenocarcinoma. Cancer Med. 2021;10(12):4004–16.PubMedPubMedCentralCrossRef
47.
48.
Fotin-Mleczek M, Duchardt KM, Lorenz C, et al. Messenger RNA-based vaccines with dual activity induce balanced TLR-7 dependent adaptive immune responses and provide antitumor activity. J Immunother. 2011;34(1):1–15.PubMedCrossRef
49.
Roychowdhury A, Jondhale M, Saldanha E, et al. Landscape of toll-like receptors expression in tumor microenvironment of triple negative breast cancer (TNBC): distinct roles of TLR4 and TLR8. Gene. 2021;792:145728.PubMedCrossRef
50.
Kiniwa Y, Miyahara Y, Wang HY, et al. CD8+ Foxp3+ regulatory T cells mediate immunosuppression in prostate cancer. Clin Cancer Res. 2007;13(23):6947–58.PubMedCrossRef
51.
Peng G, Guo Z, Kiniwa Y, et al. Toll-like receptor 8-mediated reversal of CD4+ regulatory T cell function. Science. 2005;309(5739):1380–4.PubMedCrossRef
52.
Peng G, Wang HY, Peng WY, et al. Tumor-infiltrating gammadelta T cells suppress T and dendritic cell function via mechanisms controlled by a unique toll-like receptor signaling pathway. Immunity. 2007;27(2):334–48.PubMedCrossRef
53.
Ye J, Ma CL, Hsueh EC, et al. Tumor-derived γδ regulatory T cells suppress innate and adaptive immunity through the induction of immunosenescence. J Immunol. 2013;190(5):2403–14.PubMedCrossRef
54.
Li L, Liu X, Sanders KL, et al. TLR8-mediated metabolic control of human Treg function: a mechanistic target for cancer immunotherapy. Cell Metab. 2019;29(1):103-123 e105.PubMedCrossRef
55.
Xu R, Wu M, Liu S, et al. Glucose metabolism characteristics and TLR8-mediated metabolic control of CD4(+) Treg cells in ovarian cancer cells microenvironment. Cell Death Dis. 2021;12(1):22.PubMedPubMedCentralCrossRef
56.
Ye J, Ma C, Hsueh EC, et al. TLR8 signaling enhances tumor immunity by preventing tumor-induced T-cell senescence. EMBO Mol Med. 2014;6(10):1294–311.PubMedPubMedCentralCrossRef
57.
Shang WW, Xu R, Xu T, et al. Ovarian cancer cells promote glycolysis metabolism and TLR8-mediated metabolic control of human CD4(+) T cells. Front Oncol. 2020;10:570899.PubMedPubMedCentralCrossRef
58.
Dang Y, Rutnam ZJ, Dietsch G, et al. TLR8 ligation induces apoptosis of monocytic myeloid-derived suppressor cells. J Leukoc Biol. 2018;103(1):157–64.PubMedCrossRef
59.
Fitzgerald KA, Kagan JC. Toll-like receptors and the control of immunity. Cell. 2020;180(6):1044–66.PubMedCrossRef
60.
Shayan G, Kansy BA, Gibson SP, et al. Phase Ib study of immune biomarker modulation with neoadjuvant Cetuximab and TLR8 stimulation in head and neck cancer to overcome suppressive myeloid signals. Clin Cancer Res. 2018;24(1):62–72.PubMedCrossRef
61.
Safarzadeh E, Mohammadi A, Mansoori B, et al. STAT3 silencing and TLR7/8 pathway activation repolarize and suppress myeloid-derived suppressor cells from breast cancer patients. Front Immunol. 2020;11:613215.PubMedCrossRef
62.
Hirata Y, Broquet AH, Menchén L, et al. Activation of innate immune defense mechanisms by signaling through RIG-I/IPS-1 in intestinal epithelial cells. J Immunol. 2007;179(8):5425–32.PubMedCrossRef
63.
Furr SR, Moerdyk-Schauwecker M, Grdzelishvili VZ, et al. RIG-I mediates nonsegmented negative-sense RNA virus-induced inflammatory immune responses of primary human astrocytes. Glia. 2010;58(13):1620–9.PubMedPubMedCentralCrossRef
64.
Broquet AH, Hirata Y, McAllister CS, et al. RIG-I/MDA5/MAVS are required to signal a protective IFN response in rotavirus-infected intestinal epithelium. J Immunol. 2011;186(3):1618–26.PubMedCrossRef
65.
Glas M, Coch C, Trageser D, et al. Targeting the cytosolic innate immune receptors RIG-I and MDA5 effectively counteracts cancer cell heterogeneity in glioblastoma. Stem Cells. 2013;31(6):1064–74.PubMedCrossRef
66.
67.
Wang SQ, Yang XY, Yu XF, et al. Knockdown of IGF-1R triggers viral RNA sensor MDA5- and RIG-I-mediated mitochondrial apoptosis in colonic cancer cells. Mol Ther Nucleic Acids. 2019;16:105–17.PubMedPubMedCentralCrossRef
68.
Iurescia S, Fioretti D, Rinaldi M. the innate immune signalling pathways: turning RIG-I sensor activation against cancer. Cancers (Basel). 2020;12(11):3158.CrossRef
69.
Daßler-Plenker J, Paschen A, Putschli B, et al. Direct RIG-I activation in human NK cells induces TRAIL-dependent cytotoxicity toward autologous melanoma cells. Int J Cancer. 2019;144(7):1645–56.PubMedCrossRef
70.
Brägelmann J, Lorenz C, Borchmann S, et al. MAPK-pathway inhibition mediates inflammatory reprogramming and sensitizes tumors to targeted activation of innate immunity sensor RIG-I. Nat Commun. 2021;12(1):5505.PubMedPubMedCentralCrossRef
71.
Zhou B, Li C, Yang Y, et al. RIG-I promotes cell death in hepatocellular carcinoma by inducing M1 polarization of perineal macrophages through the RIG-I/MAVS/NF-kappaB pathway. Onco Targets Ther. 2020;13:8783–94.PubMedPubMedCentralCrossRef
72.
Engel C, Brugmann G, Lambing S, et al. RIG-I resists hypoxia-induced immunosuppression and dedifferentiation. Cancer Immunol Res. 2017;5(6):455–67.PubMedCrossRef
73.
Wolf D, Fiegl H, Zeimet AG, et al. High RIG-I expression in ovarian cancer associates with an immune-escape signature and poor clinical outcome. Int J Cancer. 2020;146(7):2007–18.PubMedCrossRef
74.
Ge J, Wang J, Xiong F, et al. Epstein–Barr virus-encoded circular RNA CircBART2.2 promotes immune escape of nasopharyngeal carcinoma by regulating PD-L1. Cancer Res. 2021;81(19):5074–88.PubMedCrossRef
75.
Sultan H, Wu J, Kumai T, et al. Role of MDA5 and interferon-I in dendritic cells for T cell expansion by anti-tumor peptide vaccines in mice. Cancer Immunol Immunother. 2018;67(7):1091–103.PubMedPubMedCentralCrossRef
76.
Brown MC, Mosaheb MM, Mohme M, et al. Viral infection of cells within the tumor microenvironment mediates antitumor immunotherapy via selective TBK1-IRF3 signaling. Nat Commun. 2021;12(1):1858.PubMedPubMedCentralCrossRef
77.
Lin LL, Huang CC, Wu MT, et al. Innate immune sensor laboratory of genetics and physiology 2 suppresses tumor cell growth and functions as a prognostic marker in neuroblastoma. Cancer Sci. 2018;109(11):3494–502.PubMedPubMedCentralCrossRef
78.
Zheng W, Ranoa DRE, Huang X, et al. RIG-I-like receptor LGP2 is required for tumor control by radiotherapy. Cancer Res. 2020;80(24):5633–41.PubMedCrossRef
79.
80.
Wang Y, Miao Z, Qin X, et al. NOD2 deficiency confers a pro-tumorigenic macrophage phenotype to promote lung adenocarcinoma progression. J Cell Mol Med. 2021;25(15):7545–58.PubMedPubMedCentralCrossRef
81.
Slavik KM, Morehouse BR, Ragucci AE, et al. cGAS-like receptors sense RNA and control 3’2’-cGAMP signalling in Drosophila. Nature. 2021;597(7874):109–13.PubMedPubMedCentralCrossRef
82.
Lin Z, Wang J, Zhu W, et al. Chicken DDX1 acts as an RNA sensor to mediate IFN-β signaling pathway activation in antiviral innate immunity. Front Immunol. 2021;12:7474.
83.
Xing J, Zhang A, Du Y, et al. Identification of poly(ADP-ribose) polymerase 9 (PARP9) as a noncanonical sensor for RNA virus in dendritic cells. Nat Commun. 2021;12(1):2681.PubMedPubMedCentralCrossRef
84.
Khodarev NN, Intracellular RNA. Sensing in mammalian cells: role in stress response and cancer therapies. Int Rev Cell Mol Biol. 2019;344:31–89.PubMedCrossRef
85.
Ammi R, Waele JD, Willemen Y, et al. Poly(I:C) as cancer vaccine adjuvant: knocking on the door of medical breakthroughs. Pharmacol Ther. 2015;146:120–31.PubMedCrossRef
86.
Martins KA, Bavari S, Salazar AM. Vaccine adjuvant uses of poly-IC and derivatives. Expert Rev Vaccines. 2015;14(3):447–59.PubMedCrossRef
87.
Lu R, Groer C, Kleindl PA, et al. Formulation and preclinical evaluation of a toll-like receptor 7/8 agonist as an anti-tumoral immunomodulator. J Control Release. 2019;306:165–76.PubMedPubMedCentralCrossRef
88.
Kanzler H, Barrat FJ, Hessel EM, et al. Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists. Nat Med. 2007;13(5):552–9.PubMedCrossRef
89.
Nuhn L, Koker SD, Lint SV, et al. Nanoparticle-conjugate TLR7/8 agonist localized immunotherapy provokes safe antitumoral responses. Adv Mater. 2018;30(45):e1803397.PubMedCrossRef
90.
Doorduijn EM, Sluijter M, Salvatori DC, et al. CD4(+) T cell and NK cell interplay key to regression of MHC class i(low) tumors upon TLR7/8 agonist therapy. Cancer Immunol Res. 2017;5(8):642–53.PubMedCrossRef
91.
Wiedemann GM, Jacobi SJ, Chaloupka M, et al. A novel TLR7 agonist reverses NK cell anergy and cures RMA-S lymphoma-bearing mice. Oncoimmunology. 2016;5(7):e1189051.PubMedPubMedCentralCrossRef
92.
Vascotto F, Petschenka J, Walzer KC, et al. Intravenous delivery of the toll-like receptor 7 agonist SC1 confers tumor control by inducing a CD8+ T cell response. Oncoimmunology. 2019;8(7):1601480.PubMedPubMedCentralCrossRef
93.
Dietsch GN, Randall TD, Gottardo R, et al. Late-stage cancer patients remain highly responsive to immune activation by the selective TLR8 agonist motolimod (VTX-2337). Clin Cancer Res. 2015;21(24):5445–52.PubMedCrossRef
94.
Stephenson RM, Lim CM, Matthews M, et al. TLR8 stimulation enhances cetuximab-mediated natural killer cell lysis of head and neck cancer cells and dendritic cell cross-priming of EGFR-specific CD8+ T cells. Cancer Immunol Immunother. 2013;62(8):1347–57.PubMedPubMedCentralCrossRef
95.
Northfelt DW, Ramanathan RK, Cohen PA, et al. A phase I dose-finding study of the novel Toll-like receptor 8 agonist VTX-2337 in adult subjects with advanced solid tumors or lymphoma. Clin Cancer Res. 2014;20(14):3683–91.PubMedCrossRef
96.
Ferris RL, Saba NF, Gitlitz BJ, et al. Effect of adding motolimod to standard combination chemotherapy and cetuximab treatment of patients with squamous cell carcinoma of the head and neck: the active8 randomized clinical trial. JAMA Oncol. 2018;4(11):1583–8.PubMedPubMedCentralCrossRef
97.
Ruzicka M, Koenig LM, Formisano S, et al. RIG-I-based immunotherapy enhances survival in preclinical AML models and sensitizes AML cells to checkpoint blockade. Leukemia. 2020;34(4):1017–26.PubMedCrossRef
98.
Helms MW, Jahn-Hofmann K, Gnerlich F, et al. Utility of the RIG-I agonist triphosphate RNA for melanoma therapy. Mol Cancer Ther. 2019;18(12):2343–56.PubMedCrossRef
99.
Jiang X, Muthusamy V, Fedorova O, et al. Intratumoral delivery of RIG-I agonist SLR14 induces robust antitumor responses. J Exp Med. 2019;216(12):2854–68.PubMedPubMedCentralCrossRef
100.
Such L, Zhao F, Liu D, et al. Targeting the innate immunoreceptor RIG-I overcomes melanoma-intrinsic resistance to T cell immunotherapy. J Clin Investig. 2020;130(8):4266–81.PubMedPubMedCentral
101.
Takeda Y, Kataoka K, Yamagishi J, et al. A TLR3-specific adjuvant relieves innate resistance to PD-L1 blockade without cytokine toxicity in tumor vaccine immunotherapy. Cell Rep. 2017;19(9):1874–87.PubMedCrossRef
102.
Takeda Y, Yoshida S, Takashima K, et al. Vaccine immunotherapy with ARNAX induces tumor-specific memory T cells and durable anti-tumor immunity in mouse models. Cancer Sci. 2018;109(7):2119–29.PubMedPubMedCentralCrossRef
103.
Matsumoto M, Takeda Y, Seya T. Targeting Toll-like receptor 3 in dendritic cells for cancer immunotherapy. Expert Opin Biol Ther. 2020;20(8):937–46.PubMedCrossRef
104.
Qi X, Liu X, Matiski L, et al. RNA origami nanostructures for potent and safe anticancer immunotherapy. ACS Nano. 2020;14(4):4727–40.PubMedCrossRef
105.
Liu J, Hu Y, Guo Q, et al. Enhanced anti-melanoma efficacy of a Pim-3-targeting bifunctional small hairpin RNA via single-stranded RNA-mediated activation of plasmacytoid dendritic cells. Front Immunol. 2019;10:2721.PubMedPubMedCentralCrossRef
106.
Donzelli J, Proestler E, Riedel A, et al. Small extracellular vesicle-derived miR-574-5p regulates PGE2-biosynthesis via TLR7/8 in lung cancer. J Extracell Vesicles. 2021;10(12):e12143.PubMedCrossRef
107.
Li B, Zhu L, Lu C, et al. circNDUFB2 inhibits non-small cell lung cancer progression via destabilizing IGF2BPs and activating anti-tumor immunity. Nat Commun. 2021;12(1):295.PubMedPubMedCentralCrossRef
108.
Walton RW, Brown MC, Sacco MT, et al. Engineered oncolytic poliovirus PVSRIPO subverts MDA5-dependent innate immune responses in cancer cells. J Virol. 2018;92(19):e00879-e918.PubMedPubMedCentralCrossRef
109.
Zhang L, Dewan V, Yin H. Discovery of small molecules as multi-toll-like receptor agonists with proinflammatory and anticancer activities. J Med Chem. 2017;60(12):5029–44.PubMedCrossRef
110.
Hayashi T, Chan M, Norton JT, et al. Additive melanoma suppression with intralesional phospholipid-conjugated TLR7 agonists and systemic IL-2. Melanoma Res. 2011;21(1):66–75.PubMedPubMedCentralCrossRef
111.
Sato-Kaneko F, Yao S, Ahmadi A, et al. Combination immunotherapy with TLR agonists and checkpoint inhibitors suppresses head and neck cancer. JCI Insight. 2017;2(18):e93397.PubMedCentralCrossRef
112.
Hosoya T, Sato-Kaneko F, Ahmadi A, et al. Induction of oligoclonal CD8 T cell responses against pulmonary metastatic cancer by a phospholipid-conjugated TLR7 agonist. Proc Natl Acad Sci USA. 2018;115(29):E6836–44.PubMedPubMedCentralCrossRef
113.
Mullins SR, Vasilakos JP, Deschler K, et al. Intratumoral immunotherapy with TLR7/8 agonist MEDI9197 modulates the tumor microenvironment leading to enhanced activity when combined with other immunotherapies. J Immunother Cancer. 2019;7(1):244.PubMedPubMedCentralCrossRef
114.
Francian A, Widmer A, Olsson T, et al. Delivery of toll-like receptor agonists by complement C3-targeted liposomes activates immune cells and reduces tumour growth. J Drug Target. 2021;29(7):754–60.PubMedCrossRef
115.
Zhang H, Tang WL, Kheirolomoom A, et al. Development of thermosensitive resiquimod-loaded liposomes for enhanced cancer immunotherapy. J Control Release. 2021;330:1080–94.PubMedCrossRef
116.
Wan D, Que H, Chen L, et al. Lymph-node-targeted cholesterolized TLR7 agonist liposomes provoke a safe and durable antitumor response. Nano Lett. 2021;21(19):7960–9.PubMedCrossRef
117.
Varypataki EM, Benne N, Bouwstra J, et al. Efficient eradication of established tumors in mice with cationic liposome-based synthetic long-peptide vaccines. Cancer Immunol Res. 2017;5(3):222–33.PubMedCrossRef
118.
Zhao J, Zhang Z, Xue Y, et al. Anti-tumor macrophages activated by ferumoxytol combined or surface-functionalized with the TLR3 agonist poly (I : C) promote melanoma regression. Theranostics. 2018;8(22):6307–21.PubMedPubMedCentralCrossRef
119.
Kotting C, Hofmann L, Lotfi R, et al. Immune-stimulatory effects of curcumin on the tumor microenvironment in head and neck squamous cell carcinoma. Cancers (Basel). 2021;13(6):1335.CrossRef
120.
Ishikawa T, Kageyama S, Miyahara Y, et al. Safety and antibody immune response of CHP-NY-ESO-1 vaccine combined with poly-ICLC in advanced or recurrent esophageal cancer patients. Cancer Immunol Immunother. 2021;70(11):3081–91.PubMedCrossRef
121.
Mottas I, Bekdemir A, Cereghetti A, et al. Amphiphilic nanoparticle delivery enhances the anticancer efficacy of a TLR7 ligand via local immune activation. Biomaterials. 2019;190–191:111–20.PubMedCrossRef
122.
Smith AAA, Gale EC, Roth GA, et al. Nanoparticles presenting potent TLR7/8 agonists enhance anti-PD-L1 immunotherapy in cancer treatment. Biomacromol. 2020;21(9):3704–12.CrossRef
123.
Ni K, Luo T, Culbert A, et al. Nanoscale metal-organic framework co-delivers TLR-7 agonists and anti-CD47 antibodies to modulate macrophages and orchestrate cancer immunotherapy. J Am Chem Soc. 2020;142(29):12579–84.PubMedCrossRef
124.
Figueiredo P, Lepland A, Scodeller P, et al. Peptide-guided resiquimod-loaded lignin nanoparticles convert tumor-associated macrophages from M2 to M1 phenotype for enhanced chemotherapy. Acta Biomater. 2021;133:231–43.PubMedCrossRef
125.
Rodell CB, Arlauckas SP, Cuccarese MF, et al. TLR7/8-agonist-loaded nanoparticles promote the polarization of tumour-associated macrophages to enhance cancer immunotherapy. Nat Biomed Eng. 2018;2(8):578–88.PubMedPubMedCentralCrossRef
126.
Zhang L, Huang J, Chen X, et al. Self-assembly nanovaccine containing TLR7/8 agonist and STAT3 inhibitor enhances tumor immunotherapy by augmenting tumor-specific immune response. J Immunother Cancer. 2021;9(8):e003132.PubMedPubMedCentralCrossRef
127.
Li J, Yu X, Jiang Y, et al. Second near-infrared photothermal semiconducting polymer nanoadjuvant for enhanced cancer immunotherapy. Adv Mater. 2021;33(4):e2003458.PubMedCrossRef
128.
Wei B, Pan J, Yuan R, et al. Polarization of Tumor-Associated Macrophages by Nanoparticle-Loaded Escherichia coli Combined with Immunogenic Cell Death for Cancer Immunotherapy. Nano Lett. 2021;21(10):4231–40.PubMedCrossRef
129.
Jacobson ME, Wang-Bishop L, Becker KW, et al. Delivery of 5’-triphosphate RNA with endosomolytic nanoparticles potently activates RIG-I to improve cancer immunotherapy. Biomater Sci. 2019;7(2):547–59.PubMedCrossRef
130.
Das M, Shen L, Liu Q, et al. Nanoparticle delivery of RIG-I agonist enables effective and safe adjuvant therapy in pancreatic cancer. Mol Ther. 2019;27(3):507–17.PubMedCrossRef
131.
Han HD, Byeon Y, Jang JH, et al. In vivo stepwise immunomodulation using chitosan nanoparticles as a platform nanotechnology for cancer immunotherapy. Sci Rep. 2016;6:38348.PubMedPubMedCentralCrossRef
132.
Liu L, He H, Liang R, et al. ROS-inducing micelles sensitize tumor-associated macrophages to TLR3 stimulation for potent immunotherapy. Biomacromol. 2018;19(6):2146–55.CrossRef
133.
Pitner R, Kim J, Davis-Bergthold J, et al. Structure-based design of JOC-x, a conjugatable tumor tight junction opener to enhance cancer therapy. Sci Rep. 2019;9(1):6169.PubMedPubMedCentralCrossRef
134.
Melssen MM, Petroni GR, Chianese-Bullock KA, et al. A multipeptide vaccine plus toll-like receptor agonists LPS or polyICLC in combination with incomplete Freund’s adjuvant in melanoma patients. J Immunother Cancer. 2019;7(1):163.PubMedPubMedCentralCrossRef
135.
Patel SP, Petroni GR, Roszik J, et al. Phase I/II trial of a long peptide vaccine (LPV7) plus toll-like receptor (TLR) agonists with or without incomplete Freund’s adjuvant (IFA) for resected high-risk melanoma. J Immunother Cancer. 2021;9(8):e003220.PubMedPubMedCentralCrossRef
136.
Dillon PM, Petroni GR, Smolkin ME, et al. A pilot study of the immunogenicity of a 9-peptide breast cancer vaccine plus poly-ICLC in early stage breast cancer. J Immunother Cancer. 2017;5(1):92.PubMedPubMedCentralCrossRef
137.
Akache B, Agbayani G, Stark FC, et al. Sulfated lactosyl archaeol archaeosomes synergize with poly(I:C) to enhance the immunogenicity and efficacy of a synthetic long peptide-based vaccine in a melanoma tumor model. Pharmaceutics. 2021;13(2):257.PubMedPubMedCentralCrossRef
138.
Stevens AD, Bullock TNJ. Therapeutic vaccination targeting CD40 and TLR3 controls melanoma growth through existing intratumoral CD8 T cells without new T cell infiltration. Cancer Immunol Immunother. 2021;70(8):2139–50.PubMedCrossRef
139.
Kim SY, Kim S, Kim JE, et al. Lyophilizable and multifaceted Toll-like receptor 7/8 agonist-loaded nanoemulsion for the reprogramming of tumor microenvironments and enhanced cancer immunotherapy. ACS Nano. 2019;13(11):12671–86.PubMedCrossRef
140.
Koh J, Kim S, Lee SN, et al. Therapeutic efficacy of cancer vaccine adjuvanted with nanoemulsion loaded with TLR7/8 agonist in lung cancer model. Nanomedicine. 2021;37:102415.PubMedCrossRef
141.
Meneveau MO, Petroni GR, Salerno EP, et al. Immunogenicity in humans of a transdermal multipeptide melanoma vaccine administered with or without a TLR7 agonist. J Immunother Cancer. 2021;9(5):e002214.PubMedPubMedCentralCrossRef
142.
Dong W, Zhang H, Yin X, et al. Oral delivery of tumor microparticle vaccines activates NOD2 signaling pathway in ileac epithelium rendering potent antitumor T cell immunity. Oncoimmunology. 2017;6(3):e1282589.PubMedPubMedCentralCrossRef
143.
Koerner J, Horvath D, Herrmann VL, et al. PLGA-particle vaccine carrying TLR3/RIG-I ligand Riboxxim synergizes with immune checkpoint blockade for effective anti-cancer immunotherapy. Nat Commun. 2021;12(1):2935.PubMedPubMedCentralCrossRef
144.
145.
Johnson LR, Lee DY, Eacret JS, et al. The immunostimulatory RNA RN7SL1 enables CAR-T cells to enhance autonomous and endogenous immune function. Cell. 2021;184(19):4981-4995 e4914.PubMedCrossRef
146.
Barry KC, Hsu J, Broz ML, et al. A natural killer-dendritic cell axis defines checkpoint therapy-responsive tumor microenvironments. Nat Med. 2018;24(8):1178–91.PubMedPubMedCentralCrossRef
147.
Salem ML, Díaz-Montero CM, Al-Khami AA, et al. Recovery from cyclophosphamide-induced lymphopenia results in expansion of immature dendritic cells which can mediate enhanced prime-boost vaccination antitumor responses in vivo when stimulated with the TLR3 agonist poly(I:C). J Immunol. 2009;182(4):2030–40.PubMedCrossRef
148.
Prins RM, Soto H, Konkankit V, et al. Gene expression profile correlates with T-cell infiltration and relative survival in glioblastoma patients vaccinated with dendritic cell immunotherapy. Clin Cancer Res. 2011;17(6):1603–15.PubMedCrossRef
149.
Okada H, Kalinski P, Ueda R, et al. Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with {alpha}-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma. J Clin Oncol. 2011;29(3):330–6.PubMedCrossRef
150.
Mehrotra S, Britten CD, Chin S, et al. Vaccination with poly(IC:LC) and peptide-pulsed autologous dendritic cells in patients with pancreatic cancer. J Hematol Oncol. 2017;10(1):82.PubMedPubMedCentralCrossRef
151.
Long S, Gu Y, An Y, et al. Reovirus enhances cytotoxicity of natural killer cells against colorectal cancer via TLR3 pathway. J Transl Med. 2021;19(1):185.PubMedPubMedCentralCrossRef
152.
Reck M, Rodríguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016;375(19):1823–33.PubMedCrossRef
153.
154.
155.
Lesterhuis WJ, Bosco A, Millward MJ, et al. Dynamic versus static biomarkers in cancer immune checkpoint blockade: unravelling complexity. Nat Rev Drug Discov. 2017;16(4):264–72.PubMedCrossRef
156.
157.
Chen M, Hu S, Li Y, Jiang TT, Jin H, Feng L. Targeting nuclear acid-mediated immunity in cancer immune checkpoint inhibitor therapies. Signal Transduct Target Ther. 2020;5(1):270.PubMedPubMedCentralCrossRef
158.
Babikr F, Wan J, Xu A, et al. Distinct roles but cooperative effect of TLR3/9 agonists and PD-1 blockade in converting the immunotolerant microenvironment of irreversible electroporation-ablated tumors. Cell Mol Immunol. 2021;18(12):2632–47.PubMedCrossRef
159.
Huang CH, Mendez N, Echeagaray OH, et al. Immunostimulatory TLR7 agonist-nanoparticles together with checkpoint blockade for effective cancer immunotherapy. Adv Ther (Weinh). 2020;3(6):1900200.CrossRef
160.
Kim H, Khanna V, Kucaba TA, et al. Combination of Sunitinib and PD-L1 blockade enhances anticancer efficacy of TLR7/8 agonist-based nanovaccine. Mol Pharm. 2019;16(3):1200–10.PubMedCrossRef
161.
Narayanan JSS, Ray P, Hayashi T, et al. Irreversible electroporation combined with checkpoint blockade and TLR7 stimulation induces antitumor immunity in a murine pancreatic cancer model. Cancer Immunol Res. 2019;7(10):1714–26.PubMedCrossRef
162.
Heidegger S, Wintges A, Stritzke F, et al. RIG-I activation is critical for responsiveness to checkpoint blockade. Sci Immunol. 2019;4(39):eaau8943.PubMedCrossRef
163.
Poeck H, Wintges A, Dahl S, et al. Tumor cell-intrinsic RIG-I signaling governs synergistic effects of immunogenic cancer therapies and checkpoint inhibitors in mice. Eur J Immunol. 2021;51(6):1531–4.PubMedCrossRef
164.
Le Naour J, Liu P, Zhao L, et al. A TLR3 ligand reestablishes chemotherapeutic responses in the context of FPR1 deficiency. Cancer Discov. 2021;11(2):408–23.PubMedCrossRef
165.
Wei X, Liu L, Li X, et al. Selectively targeting tumor-associated macrophages and tumor cells with polymeric micelles for enhanced cancer chemo-immunotherapy. J Control Release. 2019;313:42–53.PubMedCrossRef
166.
Liu Z, Xie Y, Xiong Y, et al. TLR 7/8 agonist reverses oxaliplatin resistance in colorectal cancer via directing the myeloid-derived suppressor cells to tumoricidal M1-macrophages. Cancer Lett. 2020;469:173–85.PubMedCrossRef
167.
Tang L, Cai D, Qin M, et al. Oxaliplatin-based platinum(IV) prodrug bearing toll-like receptor 7 agonist for enhanced immunochemotherapy. ACS Omega. 2020;5(1):726–34.PubMedCrossRef
168.
Ringgaard L, Melander F, Eliasen R, et al. Tumor repolarization by an advanced liposomal drug delivery system provides a potent new approach for chemo-immunotherapy. Sci Adv. 2020;6(36):eaba5628.PubMedPubMedCentralCrossRef
169.
Yoshida S, Shime H, Takeda Y, et al. Toll-like receptor 3 signal augments radiation-induced tumor growth retardation in a murine model. Cancer Sci. 2018;109(4):956–65.PubMedPubMedCentralCrossRef
170.
Tan LSY, Wong B, Gangodu NR, et al. Enhancing the immune stimulatory effects of cetuximab therapy through TLR3 signalling in Epstein–Barr virus (EBV) positive nasopharyngeal carcinoma. Oncoimmunology. 2018;7(11):e1500109.PubMedPubMedCentralCrossRef
171.
Cheadle EJ, Lipowska-Bhalla G, Dovedi SJ, et al. A TLR7 agonist enhances the antitumor efficacy of obinutuzumab in murine lymphoma models via NK cells and CD4 T cells. Leukemia. 2016;31(7):1611–21.CrossRef
172.
Chow LQM, Morishima C, Eaton KD, et al. Phase Ib trial of the toll-like receptor 8 agonist, motolimod (VTX-2337), combined with cetuximab in patients with recurrent or metastatic SCCHN. Clin Cancer Res. 2017;23(10):2442–50.PubMedCrossRef
173.
Cao L, Liu S, Li Y, et al. The nuclear matrix protein SAFA surveils viral RNA and facilitates immunity by activating antiviral enhancers and super-enhancers. Cell Host Microbe. 2019;26(3):369-384.e8.PubMedCrossRef
174.
175.
Wang Y, Yuan S, Jia X, et al. Mitochondria-localised ZNFX1 functions as a dsRNA sensor to initiate antiviral responses through MAVS. Nat Cell Biol. 2019;21(11):1346–56.PubMedCrossRef
176.
Metadata
Title
Emerging role of RNA sensors in tumor microenvironment and immunotherapy
Authors
Rui Yang
Sihui Yu
Tianhan Xu
Jiawen Zhang
Sufang Wu
Publication date
01-12-2022
Publisher
BioMed Central
Published in
Journal of Hematology & Oncology / Issue 1/2022
Electronic ISSN: 1756-8722
DOI
https://doi.org/10.1186/s13045-022-01261-z

Other articles of this Issue 1/2022

Journal of Hematology & Oncology 1/2022 Go to the issue

Review

The dual role of autophagy in acute myeloid leukemia

Research

Thrombotic and bleeding complications in patients with chronic lymphocytic leukemia and severe COVID-19: a study of ERIC, the European Research Initiative on CLL

Review

ASXL1/2 mutations and myeloid malignancies

Correspondence

Evidence of SARS-CoV-2 spike protein on retrieved thrombi from COVID-19 patients

Case Report

Triple MAPK inhibition salvaged a relapsed post-BCMA CAR-T cell therapy multiple myeloma patient with a BRAF V600E subclonal mutation

Review

Crosstalk among m6A RNA methylation, hypoxia and metabolic reprogramming in TME: from immunosuppressive microenvironment to clinical application
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits